Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
I’m not down. I sold out a long while back. I’m just making observations and stating views which I am perfectly entitled to do whether I am invested or not.
Fact is investors WERE duped here by management. Unforgivable. Once the trust is gone you are done.
This is still well overvalued based on miniscule sales and a £25m market cap. Don’t talk to me about potential they’ve blown that angle!
Target SP and fair value would be 3p based on current (tiny) sales. Until that landscape changes this ain’t going nowhere.
Well said ShipwreckSheep. They have a cohesive and structured work plan for the rest of the year which they have communicated clearly to shareholders with timeframes. All very good. They have acquired the funds they require for said activities at a minuscule discount. Nothing really. The market has reacted positively. I don’t think RV and the team could do anymore. Like I say the communication is excellent to shareholders. We know exactly what is going on.
Everything is extremely positive and I am a happy shareholder with the progress being made.
467,000 shares snapped up today. That is 0.6% of the share capital in one day.
Graham Cooley had increased to over 4% last month. I wonder?
Whatever, it’s very positive. And I am very confident this will be higher than 6.25p in a few months.
I think there are just a few tired stale bulls here. For some it has been a very long wait and it’s hard to see the wood for the trees. But things are changing here at last.
The orders are coming and it will be a snowballing process.
A derisory deal and notice that Astro Zeneca themselves did not even make any comment on the deal. That’s how highly it registers on their radar.
This is basically Angle saying don’t worry we’ll do it effectively for free and hope you throw us a few breadcrumbs. £150k for six months work!? Do me a favour. It is NOT a big deal.
Newland trying to pump the SP for the next begging bowl.
Havealot - yes I think you are a bit short on research!!
Your post is wrong on several counts. Firstly You are correct they are still well short in meeting current capacity. However, once orders ramp up from multiple sectors plus new products range on stream selling to other coatings companies (!) capacity will be hit sooner than you think.
Your figure of £10m revenue to hit profit is way off the mark. The company have already stated they hit profit at between £7m and £8m.
Also, aerospace applications have completed trials and they are now starting to take orders for a growing number of parts.
There is a very substantial HCP market out there which will now legally have to use new technology to replace it and Hardide are perfectly placed to meet this need.
The future is very bright with a new proactive commercially focused board and a new CEO to be appointed. In the meantime the interim CEO is doing a good job.
Lastly a takeover here is nailed on imho at a price substantially north of this ridiculous valuation.
Win/win
Agreed. And what’s more - when and not if - this finally moves into profit amd shows growing sales it will be gobbled up by one of the larger coatings companies. Just a matter of time especially with this ridiculously cheap valuation £4.9m! Seriously? With Hardides advanced market leading technology. All this needs now is scaling up capacity which will be implemented by a larger company with the necessary capex.
Some buying today but I expect this to be much higher in the next 6-12 months min 15p
Anyone care to speculate which announcement will be the catalyst for a SP rerate?
I don’t agree IB. I don’t see any particular overlap at all with Bleepa. Bleepa is for clinicians use primarily to view clinical images and form a clinical pathway. Altera is purely a digital administrative system for patient records. If you are inferring they did not not select CareLocker to hold patient records I don’t think it was ever suggested that was part of the contract with QVH. Nothing to worry about there. :)
A number of larger trades this afternoon and after hours which all look like purchases. The price did tick up which reinforces this notion.
There is a lot of news due in the short term going by the comments in the recent investormeet.
Davey - I take your points respectfully but would point out this is NOT a Bio/Pharma stock. It’s a diagnostics stock and they produce medical devices (which are in essence an App)
AGL is also a diagnostics stock that produces a medical device.